-
1
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
R.R. Holman, S.K. Paul, and M.A. Bethel 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 15 2008 1577 1589
-
(2008)
N Engl J Med
, vol.359
, Issue.15
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
-
2
-
-
84907862963
-
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
-
S. Zoungas, J. Chalmers, and B. Neal Follow-up of blood-pressure lowering and glucose control in type 2 diabetes N Engl J Med 371 15 2014 1392 1406
-
(2014)
N Engl J Med
, vol.371
, Issue.15
, pp. 1392-1406
-
-
Zoungas, S.1
Chalmers, J.2
Neal, B.3
-
3
-
-
79956326006
-
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials
-
K. Esposito, D. Cozzolino, and G. Bellastella Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials Diabetes Obes Metab 13 7 2011 594 603
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.7
, pp. 594-603
-
-
Esposito, K.1
Cozzolino, D.2
Bellastella, G.3
-
4
-
-
84869217988
-
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: Meta-analysis
-
H. Park, C. Park, Y. Kim, and K.L. Rascati Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: Meta-analysis Ann Pharmacother 46 11 2012 1453 1469
-
(2012)
Ann Pharmacother
, vol.46
, Issue.11
, pp. 1453-1469
-
-
Park, H.1
Park, C.2
Kim, Y.3
Rascati, K.L.4
-
5
-
-
79955728359
-
Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials
-
M. Monami, F. Cremasco, and C. Lamanna Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials Diabetes Metab Res Rev 27 4 2011 362 372
-
(2011)
Diabetes Metab Res Rev
, vol.27
, Issue.4
, pp. 362-372
-
-
Monami, M.1
Cremasco, F.2
Lamanna, C.3
-
6
-
-
84895467669
-
Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - A meta-analysis from randomized clinical trials
-
Y. Zhang, J. Hong, and J. Chi Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials Diabetes Metab Res Rev 30 3 2014 241 256
-
(2014)
Diabetes Metab Res Rev
, vol.30
, Issue.3
, pp. 241-256
-
-
Zhang, Y.1
Hong, J.2
Chi, J.3
-
7
-
-
77958030736
-
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
-
A.J. Scheen, G. Charpentier, and C.J. Ostgren Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus Diabetes Metab Res Rev 26 7 2010 540 549
-
(2010)
Diabetes Metab Res Rev
, vol.26
, Issue.7
, pp. 540-549
-
-
Scheen, A.J.1
Charpentier, G.2
Ostgren, C.J.3
-
8
-
-
84877643773
-
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
-
J.L. Gross, J. Rogers, and D. Polhamus A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus BMJ Open 3 3 2013
-
(2013)
BMJ Open
, vol.3
, Issue.3
-
-
Gross, J.L.1
Rogers, J.2
Polhamus, D.3
-
10
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
B.M. Scirica, D.L. Bhatt, and E. Braunwald Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 14 2013 1317 1326
-
(2013)
N Engl J Med
, vol.369
, Issue.14
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
-
11
-
-
84883745765
-
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
-
W.B. White, C.P. Cannon, and S.R. Heller Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 14 2013 1327 1335
-
(2013)
N Engl J Med
, vol.369
, Issue.14
, pp. 1327-1335
-
-
White, W.B.1
Cannon, C.P.2
Heller, S.R.3
-
12
-
-
84859174317
-
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis
-
T. Karagiannis, P. Paschos, and K. Paletas Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis BMJ 344 2012 e1369
-
(2012)
BMJ
, vol.344
, pp. e1369
-
-
Karagiannis, T.1
Paschos, P.2
Paletas, K.3
-
13
-
-
84865492997
-
Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
-
H.R. Patil, F.J. Al Badarin, and H.A. Al Shami Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am J Cardiol 110 6 2012 826 833
-
(2012)
Am J Cardiol
, vol.110
, Issue.6
, pp. 826-833
-
-
Patil, H.R.1
Al Badarin, F.J.2
Al Shami, H.A.3
-
14
-
-
84871936025
-
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials
-
M. Monami, B. Ahren, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials Diabetes Obes Metab 15 2 2013 112 120
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.2
, pp. 112-120
-
-
Monami, M.1
Ahren, B.2
Dicembrini, I.3
Mannucci, E.4
-
15
-
-
84904007147
-
Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants
-
S. Wu, I. Hopper, M. Skiba, and H. Krum Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants Cardiovasc Ther 32 4 2014 147 158
-
(2014)
Cardiovasc Ther
, vol.32
, Issue.4
, pp. 147-158
-
-
Wu, S.1
Hopper, I.2
Skiba, M.3
Krum, H.4
-
16
-
-
84878939138
-
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
-
W.B. White, R. Pratley, and P. Fleck Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus Diabetes Obes Metab 15 7 2013 668 673
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.7
, pp. 668-673
-
-
White, W.B.1
Pratley, R.2
Fleck, P.3
-
17
-
-
84912523371
-
Dipeptidyl-peptidase-4 inhibitors and heart failure: Class effect, substance-specific effect, or chance effect?
-
E. Standl, M. Erbach, and O. Schnell Dipeptidyl-peptidase-4 inhibitors and heart failure: Class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 16 12 2014 353
-
(2014)
Curr Treat Options Cardiovasc Med
, vol.16
, Issue.12
, pp. 353
-
-
Standl, E.1
Erbach, M.2
Schnell, O.3
-
18
-
-
84901926135
-
Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
-
M. Monami, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 24 7 2014 689 697
-
(2014)
Nutr Metab Cardiovasc Dis
, vol.24
, Issue.7
, pp. 689-697
-
-
Monami, M.1
Dicembrini, I.2
Mannucci, E.3
-
19
-
-
84903315531
-
Dipeptidyl peptidase-4 inhibitors and cardiovascular safety
-
T.M. Davis Dipeptidyl peptidase-4 inhibitors and cardiovascular safety Med J Aust 200 8 2014 450 451
-
(2014)
Med J Aust
, vol.200
, Issue.8
, pp. 450-451
-
-
Davis, T.M.1
-
20
-
-
41849099939
-
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
-
G.C. Mistry, A.L. Maes, and K.C. Lasseter Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension J Clin Pharmacol 48 5 2008 592 598
-
(2008)
J Clin Pharmacol
, vol.48
, Issue.5
, pp. 592-598
-
-
Mistry, G.C.1
Maes, A.L.2
Lasseter, K.C.3
-
21
-
-
84855481995
-
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
-
O.E. Johansen, D. Neubacher, and M. von Eynatten Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 11 2012 3
-
(2012)
Cardiovasc Diabetol
, vol.11
, pp. 3
-
-
Johansen, O.E.1
Neubacher, D.2
Von Eynatten, M.3
-
22
-
-
77957231074
-
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans
-
A. Marney, S. Kunchakarra, L. Byrne, and N.J. Brown Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans Hypertension 56 4 2010 728 733
-
(2010)
Hypertension
, vol.56
, Issue.4
, pp. 728-733
-
-
Marney, A.1
Kunchakarra, S.2
Byrne, L.3
Brown, N.J.4
-
23
-
-
79953217579
-
The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses
-
A. Ring, A. Port, and E.U. Graefe-Mody The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses Br J Clin Pharmacol 72 1 2011 39 50
-
(2011)
Br J Clin Pharmacol
, vol.72
, Issue.1
, pp. 39-50
-
-
Ring, A.1
Port, A.2
Graefe-Mody, E.U.3
-
24
-
-
84884198401
-
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients
-
M. Ayaori, N. Iwakami, and H. Uto-Kondo Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients J Am Heart Assoc 2 1 2013 e003277
-
(2013)
J Am Heart Assoc
, vol.2
, Issue.1
, pp. e003277
-
-
Ayaori, M.1
Iwakami, N.2
Uto-Kondo, H.3
-
25
-
-
84905858733
-
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
-
K. Nakamura, H. Oe, and H. Kihara DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study Cardiovasc Diabetol 13 1 2014 110
-
(2014)
Cardiovasc Diabetol
, vol.13
, Issue.1
, pp. 110
-
-
Nakamura, K.1
Oe, H.2
Kihara, H.3
-
26
-
-
34447267513
-
Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
-
R.E. Amori, J. Lau, and A.G. Pittas Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis JAMA 298 2 2007 194 206
-
(2007)
JAMA
, vol.298
, Issue.2
, pp. 194-206
-
-
Amori, R.E.1
Lau, J.2
Pittas, A.G.3
-
27
-
-
79960019675
-
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: Focus on incretins
-
S. Ansar, J. Koska, and P.D. Reaven Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: Focus on incretins Cardiovasc Diabetol 10 2011 61
-
(2011)
Cardiovasc Diabetol
, vol.10
, pp. 61
-
-
Ansar, S.1
Koska, J.2
Reaven, P.D.3
-
28
-
-
79951933599
-
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
-
A.J. Tremblay, B. Lamarche, and C.F. Deacon Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes Diabetes Obes Metab 13 4 2011 366 373
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.4
, pp. 366-373
-
-
Tremblay, A.J.1
Lamarche, B.2
Deacon, C.F.3
-
29
-
-
33746690405
-
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
-
N. Matikainen, S. Manttari, and A. Schweizer Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 9 2006 2049 2057
-
(2006)
Diabetologia
, vol.49
, Issue.9
, pp. 2049-2057
-
-
Matikainen, N.1
Manttari, S.2
Schweizer, A.3
-
30
-
-
84859463659
-
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: A randomised double-blind placebo-controlled study
-
B. Eliasson, D. Moller-Goede, and K. Eeg-Olofsson Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: A randomised double-blind placebo-controlled study Diabetologia 55 4 2012 915 925
-
(2012)
Diabetologia
, vol.55
, Issue.4
, pp. 915-925
-
-
Eliasson, B.1
Moller-Goede, D.2
Eeg-Olofsson, K.3
-
31
-
-
34547660561
-
Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
-
B.J. Goldstein, M.N. Feinglos, and J.K. Lunceford Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 30 8 2007 1979 1987
-
(2007)
Diabetes Care
, vol.30
, Issue.8
, pp. 1979-1987
-
-
Goldstein, B.J.1
Feinglos, M.N.2
Lunceford, J.K.3
-
32
-
-
33846817233
-
Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial
-
M.A. Nauck, G. Meininger, and D. Sheng Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial Diabetes Obes Metab 9 2 2007 194 205
-
(2007)
Diabetes Obes Metab
, vol.9
, Issue.2
, pp. 194-205
-
-
Nauck, M.A.1
Meininger, G.2
Sheng, D.3
-
33
-
-
65549123794
-
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial
-
M. Jadzinsky, A. Pfutzner, and E. Paz-Pacheco Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial Diabetes Obes Metab 11 6 2009 611 622
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.6
, pp. 611-622
-
-
Jadzinsky, M.1
Pfutzner, A.2
Paz-Pacheco, E.3
-
34
-
-
60249099791
-
Vildagliptin: A new oral treatment for type 2 diabetes mellitus
-
C. Mathieu, and E. Degrande Vildagliptin: A new oral treatment for type 2 diabetes mellitus Vasc Health Risk Manag 4 6 2008 1349 1360
-
(2008)
Vasc Health Risk Manag
, vol.4
, Issue.6
, pp. 1349-1360
-
-
Mathieu, C.1
Degrande, E.2
-
35
-
-
84857573175
-
Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide
-
S.N. Iyer, A.J. Drake 3rd, and R.L. West Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide Endocr Pract 18 1 2012 e10 e13
-
(2012)
Endocr Pract
, vol.18
, Issue.1
, pp. e10-e13
-
-
Iyer, S.N.1
Drake, A.J.2
West, R.L.3
-
36
-
-
84896731936
-
Pancreatic safety of incretin-based drugs - FDA and EMA assessment
-
A.G. Egan, E. Blind, and K. Dunder Pancreatic safety of incretin-based drugs - FDA and EMA assessment N Engl J Med 370 9 2014 794 797
-
(2014)
N Engl J Med
, vol.370
, Issue.9
, pp. 794-797
-
-
Egan, A.G.1
Blind, E.2
Dunder, K.3
-
37
-
-
18144401971
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
-
R.A. DeFronzo, R.E. Ratner, and J. Han Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 5 2005 1092 1100
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1092-1100
-
-
Defronzo, R.A.1
Ratner, R.E.2
Han, J.3
-
38
-
-
17144371646
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
-
D.M. Kendall, M.C. Riddle, and J. Rosenstock Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 5 2005 1083 1091
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1083-1091
-
-
Kendall, D.M.1
Riddle, M.C.2
Rosenstock, J.3
-
39
-
-
34249891874
-
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
-
D. Kim, L. MacConell, and D. Zhuang Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 6 2007 1487 1493
-
(2007)
Diabetes Care
, vol.30
, Issue.6
, pp. 1487-1493
-
-
Kim, D.1
Macconell, L.2
Zhuang, D.3
-
40
-
-
83655184782
-
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
-
B. Zinman, W.E. Schmidt, and A. Moses Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme Diabetes Obes Metab 14 1 2012 77 82
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.1
, pp. 77-82
-
-
Zinman, B.1
Schmidt, W.E.2
Moses, A.3
-
41
-
-
62449169287
-
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
-
M. Nauck, A. Frid, and K. Hermansen Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study Diabetes Care 32 1 2009 84 90
-
(2009)
Diabetes Care
, vol.32
, Issue.1
, pp. 84-90
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
-
42
-
-
84922392829
-
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes
-
L. Kuritzky, G. Umpierrez, and J.M. Ekoe Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes Postgrad Med 126 6 2014 60 72
-
(2014)
Postgrad Med
, vol.126
, Issue.6
, pp. 60-72
-
-
Kuritzky, L.1
Umpierrez, G.2
Ekoe, J.M.3
-
43
-
-
84908099303
-
Albiglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
-
J.M. Trujillo, and W. Nuffer Albiglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes Ann Pharmacother 48 11 2014 1494 1501
-
(2014)
Ann Pharmacother
, vol.48
, Issue.11
, pp. 1494-1501
-
-
Trujillo, J.M.1
Nuffer, W.2
-
44
-
-
84899585635
-
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study
-
R.E. Pratley, M.A. Nauck, and A.H. Barnett Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2 4 2014 289 297
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, Issue.4
, pp. 289-297
-
-
Pratley, R.E.1
Nauck, M.A.2
Barnett, A.H.3
-
46
-
-
79960777404
-
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis
-
N.R. Pinelli, and K.M. Hurren Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis Ann Pharmacother 45 7-8 2011 850 860
-
(2011)
Ann Pharmacother
, vol.45
, Issue.7-8
, pp. 850-860
-
-
Pinelli, N.R.1
Hurren, K.M.2
-
47
-
-
59449101432
-
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial
-
A. Garber, R. Henry, and R. Ratner Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 9662 2009 473 481
-
(2009)
Lancet
, vol.373
, Issue.9662
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
-
48
-
-
56549107405
-
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
-
H. Linnebjerg, S. Park, and P.A. Kothare Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Regul Pept 151 1-3 2008 123 129
-
(2008)
Regul Pept
, vol.151
, Issue.1-3
, pp. 123-129
-
-
Linnebjerg, H.1
Park, S.2
Kothare, P.A.3
-
49
-
-
35748957503
-
The physiology of glucagon-like peptide 1
-
J.J. Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 4 2007 1409 1439
-
(2007)
Physiol Rev
, vol.87
, Issue.4
, pp. 1409-1439
-
-
Holst, J.J.1
-
50
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
-
R.M. Bergenstal, C. Wysham, and L. MacConell Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial The Lancet 376 9739 2010 431 439
-
(2010)
The Lancet
, vol.376
, Issue.9739
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
-
51
-
-
79955661908
-
DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
-
T. Blevins, J. Pullman, and J. Malloy DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Meta 96 5 2011 1301 1310
-
(2011)
J Clin Endocrinol Meta
, vol.96
, Issue.5
, pp. 1301-1310
-
-
Blevins, T.1
Pullman, J.2
Malloy, J.3
-
52
-
-
67649666737
-
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
-
J.B. Buse, J. Rosenstock, and G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 9683 2009 39 47
-
(2009)
Lancet
, vol.374
, Issue.9683
, pp. 39-47
-
-
Buse, J.B.1
Rosenstock, J.2
Sesti, G.3
-
53
-
-
84855489636
-
Glucagon like peptide-1 receptor expression in the human thyroid gland
-
B. Gier, P.C. Butler, and C.K. Lai Glucagon like peptide-1 receptor expression in the human thyroid gland J Clin Endocrinol Metab 97 1 2012 121 131
-
(2012)
J Clin Endocrinol Metab
, vol.97
, Issue.1
, pp. 121-131
-
-
Gier, B.1
Butler, P.C.2
Lai, C.K.3
-
54
-
-
77950228684
-
Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
-
L. Bjerre Knudsen, L.W. Madsen, and S. Andersen Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 151 4 2010 1473 1486
-
(2010)
Endocrinology
, vol.151
, Issue.4
, pp. 1473-1486
-
-
Bjerre Knudsen, L.1
Madsen, L.W.2
Andersen, S.3
-
55
-
-
84895787341
-
Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
-
M. Monami, I. Dicembrini, and C. Nardini Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials Diabetes Res Clin Pract 103 2 2014 269 275
-
(2014)
Diabetes Res Clin Pract
, vol.103
, Issue.2
, pp. 269-275
-
-
Monami, M.1
Dicembrini, I.2
Nardini, C.3
-
56
-
-
84899029163
-
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies
-
L. Li, J. Shen, and M.M. Bala Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies BMJ 348 2014 g2366
-
(2014)
BMJ
, vol.348
, pp. g2366
-
-
Li, L.1
Shen, J.2
Bala, M.M.3
-
57
-
-
84872055241
-
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity
-
M.H. Noyan-Ashraf, E.A. Shikatani, and I. Schuiki A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity Circulation 127 1 2013 74 85
-
(2013)
Circulation
, vol.127
, Issue.1
, pp. 74-85
-
-
Noyan-Ashraf, M.H.1
Shikatani, E.A.2
Schuiki, I.3
-
58
-
-
84860807487
-
Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia
-
J. Lonborg, H. Kelbaek, and N. Vejlstrup Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia Circ Cardiovasc Interv 5 2 2012 288 295
-
(2012)
Circ Cardiovasc Interv
, vol.5
, Issue.2
, pp. 288-295
-
-
Lonborg, J.1
Kelbaek, H.2
Vejlstrup, N.3
-
59
-
-
79952694840
-
Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes
-
R. Ratner, J. Han, and D. Nicewarner Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes Cardiovasc Diabetol 10 2011 22
-
(2011)
Cardiovasc Diabetol
, vol.10
, pp. 22
-
-
Ratner, R.1
Han, J.2
Nicewarner, D.3
-
60
-
-
76949099016
-
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study
-
A. Gill, B.J. Hoogwerf, and J. Burger Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study Cardiovasc Diabetol 9 2010 6
-
(2010)
Cardiovasc Diabetol
, vol.9
, pp. 6
-
-
Gill, A.1
Hoogwerf, B.J.2
Burger, J.3
-
61
-
-
84879800350
-
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials
-
B. Wang, J. Zhong, and H. Lin Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials Diabetes Obes Metab 15 8 2013 737 749
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.8
, pp. 737-749
-
-
Wang, B.1
Zhong, J.2
Lin, H.3
-
62
-
-
84873554686
-
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis
-
L.E. Robinson, T.A. Holt, and K. Rees Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis BMJ Open 3 1 2013
-
(2013)
BMJ Open
, vol.3
, Issue.1
-
-
Robinson, L.E.1
Holt, T.A.2
Rees, K.3
-
63
-
-
84871825708
-
Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
-
C. Irace, S. De Luca, and E. Shehaj Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research Diab Vasc Dis Res 10 1 2013 72 77
-
(2013)
Diab Vasc Dis Res
, vol.10
, Issue.1
, pp. 72-77
-
-
Irace, C.1
De Luca, S.2
Shehaj, E.3
-
64
-
-
84895762544
-
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
-
M. Rizzo, M. Chandalia, and A.M. Patti Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study Cardiovasc Diabetol 13 1 2014 49
-
(2014)
Cardiovasc Diabetol
, vol.13
, Issue.1
, pp. 49
-
-
Rizzo, M.1
Chandalia, M.2
Patti, A.M.3
-
65
-
-
84875385071
-
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
-
E. Chiquette, P.P. Toth, and G. Ramirez Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers Vasc Health Risk Manag 8 2012 621 629
-
(2012)
Vasc Health Risk Manag
, vol.8
, pp. 621-629
-
-
Chiquette, E.1
Toth, P.P.2
Ramirez, G.3
-
66
-
-
77953828230
-
DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks
-
J.B. Buse, D.J. Drucker, and K.L. Taylor DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 33 6 2010 1255 1261
-
(2010)
Diabetes Care
, vol.33
, Issue.6
, pp. 1255-1261
-
-
Buse, J.B.1
Drucker, D.J.2
Taylor, K.L.3
-
67
-
-
78851471129
-
Liraglutide - Overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
-
M.J. Davies, R. Kela, and K. Khunti Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes Diabetes Obes Metab 13 3 2011 207 220
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.3
, pp. 207-220
-
-
Davies, M.J.1
Kela, R.2
Khunti, K.3
-
68
-
-
84883324640
-
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
-
J. Rosenstock, D. Raccah, and L. Koranyi Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 36 10 2013 2945 2951
-
(2013)
Diabetes Care
, vol.36
, Issue.10
, pp. 2945-2951
-
-
Rosenstock, J.1
Raccah, D.2
Koranyi, L.3
-
69
-
-
84904963065
-
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin
-
B. Ahren, S.L. Johnson, and M. Stewart HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin Diabetes Care 37 8 2014 2141 2148
-
(2014)
Diabetes Care
, vol.37
, Issue.8
, pp. 2141-2148
-
-
Ahren, B.1
Johnson, S.L.2
Stewart, M.3
-
70
-
-
84919772916
-
HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
-
P.N. Weissman, M.C. Carr, and J. Ye HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea Diabetologia 57 12 2014 2475 2484
-
(2014)
Diabetologia
, vol.57
, Issue.12
, pp. 2475-2484
-
-
Weissman, P.N.1
Carr, M.C.2
Ye, J.3
-
71
-
-
70350619609
-
Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study
-
A. Astrup, S. Rossner, and L. Van Gaal Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study Lancet 374 9701 2009 1606 1616
-
(2009)
Lancet
, vol.374
, Issue.9701
, pp. 1606-1616
-
-
Astrup, A.1
Rossner, S.2
Van Gaal, L.3
-
72
-
-
84908275752
-
SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
-
R.G. Moses, S. Colagiuri, and C. Pollock SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes Australas Med J 7 10 2014 405 415
-
(2014)
Australas Med J
, vol.7
, Issue.10
, pp. 405-415
-
-
Moses, R.G.1
Colagiuri, S.2
Pollock, C.3
-
73
-
-
84882251091
-
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis
-
D. Vasilakou, T. Karagiannis, and E. Athanasiadou Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis Ann Intern Med 159 4 2013 262 274
-
(2013)
Ann Intern Med
, vol.159
, Issue.4
, pp. 262-274
-
-
Vasilakou, D.1
Karagiannis, T.2
Athanasiadou, E.3
-
74
-
-
77953857048
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial
-
C.J. Bailey, J.L. Gross, and A. Pieters Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial Lancet 375 9733 2010 2223 2233
-
(2010)
Lancet
, vol.375
, Issue.9733
, pp. 2223-2233
-
-
Bailey, C.J.1
Gross, J.L.2
Pieters, A.3
-
75
-
-
84888059660
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial
-
J.P. Wilding, G. Charpentier, and P. Hollander Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial Int J Clin Pract 67 12 2013 1267 1282
-
(2013)
Int J Clin Pract
, vol.67
, Issue.12
, pp. 1267-1282
-
-
Wilding, J.P.1
Charpentier, G.2
Hollander, P.3
-
76
-
-
84931008068
-
Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes
-
Poster #764
-
D. Matthews, G. Fulcher, and V. Perkovic Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes European Association of Diabetes (EASD) 2012 Poster #764
-
(2012)
European Association of Diabetes (EASD)
-
-
Matthews, D.1
Fulcher, G.2
Perkovic, V.3
-
77
-
-
84931007392
-
Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting
-
E.K. Buysman, W. Chow, H.J. Henk, and M.F. Rupnow Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting Curr Med Res Opin 2014 1 7
-
(2014)
Curr Med Res Opin
, pp. 1-7
-
-
Buysman, E.K.1
Chow, W.2
Henk, H.J.3
Rupnow, M.F.4
-
78
-
-
84901455931
-
Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
-
H.U. Haring, L. Merker, and E. Seewaldt-Becker Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 37 6 2014 1650 1659
-
(2014)
Diabetes Care
, vol.37
, Issue.6
, pp. 1650-1659
-
-
Haring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
79
-
-
84885952950
-
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
-
H.U. Haring, L. Merker, and E. Seewaldt-Becker Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 36 11 2013 3396 3404
-
(2013)
Diabetes Care
, vol.36
, Issue.11
, pp. 3396-3404
-
-
Haring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
80
-
-
84866003015
-
Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range
-
C.J. Bailey, N. Iqbal, C. T'joen, and J.F. List Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range Diabetes Obes Metab 14 10 2012 951 959
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.10
, pp. 951-959
-
-
Bailey, C.J.1
Iqbal, N.2
T'Joen, C.3
List, J.F.4
-
81
-
-
84883810898
-
Urinary tract infections in patients with diabetes treated with dapagliflozin
-
K.M. Johnsson, A. Ptaszynska, and B. Schmitz Urinary tract infections in patients with diabetes treated with dapagliflozin J Diabetes Complications 27 5 2013 473 478
-
(2013)
J Diabetes Complications
, vol.27
, Issue.5
, pp. 473-478
-
-
Johnsson, K.M.1
Ptaszynska, A.2
Schmitz, B.3
-
82
-
-
84882290089
-
Genital mycotic infections in patients with diabetes
-
P. Nyirjesy, and J.D. Sobel Genital mycotic infections in patients with diabetes Postgrad Med 125 3 2013 33 46
-
(2013)
Postgrad Med
, vol.125
, Issue.3
, pp. 33-46
-
-
Nyirjesy, P.1
Sobel, J.D.2
-
83
-
-
84934288630
-
Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events
-
A. Ptaszynska, K.M. Johnsson, and S.J. Parikh Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events Drug Saf 37 10 2014 815
-
(2014)
Drug Saf
, vol.37
, Issue.10
, pp. 815
-
-
Ptaszynska, A.1
Johnsson, K.M.2
Parikh, S.J.3
-
84
-
-
84914689445
-
A safety evaluation of canagliflozin: A first-in-class treatment for type 2 diabetes
-
L.D. Boyle, and J.P. Wilding A safety evaluation of canagliflozin: A first-in-class treatment for type 2 diabetes Expert Opin Drug Saf 13 11 2014 1535 1544
-
(2014)
Expert Opin Drug Saf
, vol.13
, Issue.11
, pp. 1535-1544
-
-
Boyle, L.D.1
Wilding, J.P.2
-
85
-
-
84911028030
-
Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes
-
B. Peene, and K. Benhalima Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes Ther Adv Endocrinol Metab 5 5 2014 124 136
-
(2014)
Ther Adv Endocrinol Metab
, vol.5
, Issue.5
, pp. 124-136
-
-
Peene, B.1
Benhalima, K.2
-
86
-
-
84919681923
-
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus
-
M.R. Weir, A. Januszewicz, and R.E. Gilbert Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus J Clin Hypertens (Greenwich) 16 12 2014 875 882
-
(2014)
J Clin Hypertens (Greenwich)
, vol.16
, Issue.12
, pp. 875-882
-
-
Weir, M.R.1
Januszewicz, A.2
Gilbert, R.E.3
-
87
-
-
84921936523
-
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
-
I. Tikkanen, K. Narko, and C. Zeller Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension Diabetes Care 2014
-
(2014)
Diabetes Care
-
-
Tikkanen, I.1
Narko, K.2
Zeller, C.3
-
88
-
-
80155124676
-
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
-
M.A. Nauck, S. Del Prato, and J.J. Meier Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 9 2011 2015 2022
-
(2011)
Diabetes Care
, vol.34
, Issue.9
, pp. 2015-2022
-
-
Nauck, M.A.1
Del Prato, S.2
Meier, J.J.3
-
89
-
-
84892488179
-
Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years
-
J.P. Wilding, V. Woo, and K. Rohwedder Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years Diabetes Obes Metab 16 2 2014 124 136
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.2
, pp. 124-136
-
-
Wilding, J.P.1
Woo, V.2
Rohwedder, K.3
-
90
-
-
84903792530
-
Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM)
-
J. Rosenstock, A. Jelaska, and F. Wang Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM) Can J Diabetes 2013 37
-
(2013)
Can J Diabetes
, pp. 37
-
-
Rosenstock, J.1
Jelaska, A.2
Wang, F.3
-
91
-
-
84884167643
-
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
-
W.T. Cefalu, L.A. Leiter, and K.H. Yoon Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 9896 2013 941 950
-
(2013)
Lancet
, vol.382
, Issue.9896
, pp. 941-950
-
-
Cefalu, W.T.1
Leiter, L.A.2
Yoon, K.H.3
-
92
-
-
84892959743
-
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
-
D.Z. Cherney, B.A. Perkins, and N. Soleymanlou The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus Cardiovasc Diabetol 13 2014 28
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 28
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
-
93
-
-
84903175006
-
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
-
J. Dziuba, P. Alperin, and J. Racketa Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes Diabetes Obes Metab 16 7 2014 628 635
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.7
, pp. 628-635
-
-
Dziuba, J.1
Alperin, P.2
Racketa, J.3
-
94
-
-
84892649479
-
Standards of medical care in diabetes - 2014
-
American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 suppl 1 2014 S14 S80
-
(2014)
Diabetes Care
, vol.37
, pp. S14-S80
-
-
-
95
-
-
84884550328
-
Rationale and design of the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE)
-
D.M. Nathan, J.B. Buse, and S.E. Kahn Rationale and design of the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE) Diabetes Care 36 8 2013 2254 2261
-
(2013)
Diabetes Care
, vol.36
, Issue.8
, pp. 2254-2261
-
-
Nathan, D.M.1
Buse, J.B.2
Kahn, S.E.3
|